Comparative Study of FGF21 agonist
Direct comparison study with FGF21 agonist
Today, we would like to introduce a demonstration example of a drug efficacy evaluation study targeting FGF21 using STAMTM mice.
In 2023, positive results were announced for Efruxifermin from Akero in the US and Pegozafermin from 89bio in Israel in Phase 2b, and future developments are expected. As of October 2024, Table 1 summarizes the clinical trials and non-clinical studies registered in Clinical Trials gov.
Table 1. Development status of FGF21 analogs for NASH
As listed in Table 1, the STAM mouse is a model that has been evaluated for the FGF21 analogues Pegbelfermin and Pegozafermin. For example, 89bio is the first company in the world to report that administering Pegozafermin to STAM mice suppresses liver carcinogenesis.
https://www.89bio.com/wp-content/uploads/2023/06/EASL-2023.pdf
By using the STAMTM mouse, which has a track record of evaluating Pegozafermin, which is an FGF21 analog and has been developed in advance, it is possible to compare it head-to-head with your own test substance, giving the developed product an advantage.
Are you interested in evaluating the efficacy of a test substance targeting the FGF21 pathway using the STAM mouse, the world’s first MASH/NASH model developed by our company?